Tasman Therapeutics Announces Strategic Partnership with Osmind to Advance R-107 for Depressive Disorders

Collaboration will leverage Osmind's real-world evidence platform and national clinical network to support Tasman's pivotal Phase 3 ROCKET program, launch readiness, and growth. R-107 is an investigational oral extended-release ketamine product designed for a…



